A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate survival, response rate, safety and tolerability of
YM155 given in combination with docetaxel as first-line treatment in subjects with human
epidermal growth factor 2 non-overexpressing (HER2 negative) metastatic breast cancer.